Objective:To develop a method for the determination of Zinc gluconate and citric acid in Shanpu-Jianpi granule. Methods:The air-acetylene was selected as flame type, the detection wavelength was 213.9 nm, the gas flow rate was 0.9 L/min, the burner height was 7.2 mm, and deuterium lamp was used as background correction. The width of passband was 1.0 nm. Titration, sodium hydroxide was used to determine the citric acid with phenolphthalein as an indicator.Results:The content of Zinc Meletin, exhibited good linearity ( r=0.999 8) among the ranges of 0.1-2.0 μg/ml and the average recovery was 94.06% ( RSD=1.67%). The average recovery of citric acid was 94.65% ( RSD=0.91%). Conclusions:The method is simple, accurate and high sensitivity which can be used for determination of Zinc gluconate and citric acid in Shanpu-Jianpi granule.

Objective To clarify the impact of GATA2 overexpression on transcriptional expression in chicken preadipocytes.Methods Chicken preadipocytes ICP1 were cultivated,pCMV-myc-GATA2 or pCMV-myc plasmid was transfected,Western blot was used to verify the overexpression of GATA2 in cells,RNA-seq was used to study the changes in cell transcriptome expression caused by overexpression of GATA2,ChIP-seq was used to study the binding of GATA2 in the genome,Real time PCR was used to verify some differentially expressed genes,ChIP-PCR was used to verify the collection of GATA2 to TAF3 genes.Results Transfection of pCMV-myc-GATA2 allowed overexpression of GATA2 protein in ICP1 cells;overexpression of GATA2 resulted in up-regulation of 942 genes and down-regulation of 840 genes in ICP1 cells(P＜0.05),and enrichment analysis showed that differentially ex-pressed genes were associated with ribosome and mitochondrial structure and function(P＜0.01);GESA analysis showed that the expression of GATA2-overexpressing ICP1 cells showed up-regulation of RNA polymerase Ⅱ tran-scription initiation complex,ribosome biogenesis,propionate metabolism,and oxidative phosphorylation-related gene sets,and down-regulation of histone lysine N-methyltransferase,nuclear transcription repression complex formation,adipokines,and calcium ions signaling pathway-related gene sets.ChIP-seq in ICP1 cells identified 2833 GATA2-binding genomic peaks involving 2018 genes.motif analysis revealed GATA2-binding(T/A)GATA motifs;enrich-ment analysis showed that these genes are involved in embryonic development,signaling,cellular metabolism,and cell-cell interactions.Differently expressed genes and GATA2-binding genes were taken to intersect to obtain 105 genes,and enrichment analysis showed that these genes were associated with transcription,post-transcriptional regu-lation,cell-cell interactions,signaling,and cell cycle(P＜0.001).Conclusion GATA2 can at least bind to the genome of chicken preadipocytes to regulate their transcriptome expression patterns.

OBJECTIVE To systematically evaluate the efficacy and safety of glucokinase activators in the treatment of type 2 diabetes mellitus. METHODS PubMed， Cochrane Library， Web of Science， Embase and CNKI databases were searched from the inception to March 2022. Randomized controlled trials about glucokinase activators versus placebo （or other oral hypoglycemic agents） in the treatment of type 2 diabetes were included， data were extracted and meta-analysis was analyzed using RevMan 5.4 software. RESULTS A total of 9 studies with 215 0 patients were included. In terms of hypoglycemic effect， compared with control group， glucokinase activators significantly reduced glycosylated hemoglobin （HbA1c） [MD＝－0.40， 95%CI（－0.53， －0.26）， P＜0.000 01]， fasting blood glucose[MD＝－0.53， 95%CI（－0.85， －0.20）， P＝0.001] and 2 h postprandial blood glucose [MD＝－2.28， 95%CI（－2.68， －1.88）， P＜0.000 01] in diabetic patients. In terms of safety， the incidence of hypoglycemia caused by glucokinase activators was higher than control group on the whole [RR＝1.55， 95%CI（1.20，2.01）， P＝ 0.000 8]. According to the subgroup analysis of organs activated by glucokinase activator， the incidence of hypoglycemia in the pancreas-liver dual activator group [RR＝1.44， 95%CI（1.11，1.89）， P＝0.007] and liver-selective activator group [RR＝2.26， 95%CI（1.02，5.03）， P＝0.05] was higher than that in the control group， the difference was statistically significant. CONCLUSIONS Glucokinase activators can effectively reduce HbA1c， fasting blood glucose and 2 h postprandial blood glucose in patients with type 2 diabetes， but the risk of hypoglycemia remains to be addressed.